MARCH BIOSCIENCES INC
Transforming Patient Care by Unlocking New Target Spaces
Houston, United States · Founded 2024 · $32.4M raised
- Headquarters
- Houston, Texas
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- march.bio
- Total Funding
- $32.4M
- Last Round
- $28.4M Series AOct 2024
- Rounds
- 2
About
March Biosciences is a Houston, Texas clinical-stage cell therapy company focused on developing CAR-T cell therapies for challenging hematological cancers. Its lead asset, MB-105, is a CD5-targeted CAR-T therapy in Phase 2 clinical trials for relapsed/refractory T-cell lymphoma and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. The company was launched from Baylor College of Medicine's Center for Cell and Gene Therapy and has raised over $53 million to date.
Summary
MARCH BIOSCIENCES INC is a Biotech company based in Houston, United States, founded in 2024. It has raised $32.4M in total across 2 rounds, most recently a $28.4M Series A round in Oct 2024. Investors include Mission BioCapital, 4BIO Capital and Cancer Focus Fund.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Oct 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company